Compare Stocks: GEHC, LLY, NVO, and HIMS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GEHC GE HealthCare Technologies	$72.48 -1.1%	$67.47	$58.75 ▼ $89.77	$33.11B	0.69	3.14 million shs	2.96 million shs
HIMS Hims & Hers Health	$31.63 +6.0%	$32.27	$13.74 ▼ $65.30	$6.96B	2.4	13.38 million shs	9.58 million shs
LLY Eli Lilly and Company	$1,175.01 -1.2%	$1,187.82	$712.05 ▼ $1,292.65	$1.12T	0.51	2.89 million shs	2.73 million shs
NVO Novo Nordisk A/S	$46.27 -2.0%	$47.98	$35.12 ▼ $64.16	$210.70B	0.76	14.69 million shs	12.99 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GEHC GE HealthCare Technologies	-1.13%	-2.13%	+13.06%	+16.27%	-2.40%
HIMS Hims & Hers Health	+5.89%	-1.00%	+7.58%	+21.09%	-28.23%
LLY Eli Lilly and Company	-1.38%	-5.76%	-3.89%	+6.30%	+59.96%
NVO Novo Nordisk A/S	-2.04%	-0.07%	-9.09%	+1.52%	-18.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GEHC GE HealthCare Technologies	$72.48 -1.1%	$67.47	$58.75 ▼ $89.77	$33.11B	0.69	3.14 million shs	2.96 million shs
HIMS Hims & Hers Health	$31.63 +6.0%	$32.27	$13.74 ▼ $65.30	$6.96B	2.4	13.38 million shs	9.58 million shs
LLY Eli Lilly and Company	$1,175.01 -1.2%	$1,187.82	$712.05 ▼ $1,292.65	$1.12T	0.51	2.89 million shs	2.73 million shs
NVO Novo Nordisk A/S	$46.27 -2.0%	$47.98	$35.12 ▼ $64.16	$210.70B	0.76	14.69 million shs	12.99 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GEHC GE HealthCare Technologies	-1.13%	-2.13%	+13.06%	+16.27%	-2.40%
HIMS Hims & Hers Health	+5.89%	-1.00%	+7.58%	+21.09%	-28.23%
LLY Eli Lilly and Company	-1.38%	-5.76%	-3.89%	+6.30%	+59.96%
NVO Novo Nordisk A/S	-2.04%	-0.07%	-9.09%	+1.52%	-18.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GEHC GE HealthCare Technologies	2.48	Hold	$77.73	7.24% Upside
HIMS Hims & Hers Health	2.19	Hold	$32.50	2.75% Upside
LLY Eli Lilly and Company	2.83	Moderate Buy	$1,292.18	9.97% Upside
NVO Novo Nordisk A/S	2.16	Hold	$64.94	40.36% Upside

Current Analyst Ratings Breakdown

Latest GEHC, LLY, NVO, and HIMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	NVO Novo Nordisk A/S	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Sell
8/26/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/24/2026	HIMS Hims & Hers Health	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$27.00 ➝ $32.00
8/21/2026	HIMS Hims & Hers Health	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$39.00 ➝ $35.00
8/19/2026	GEHC GE HealthCare Technologies	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$79.00
8/12/2026	GEHC GE HealthCare Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
8/12/2026	NVO Novo Nordisk A/S	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$47.00
8/12/2026	NVO Novo Nordisk A/S	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/11/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/11/2026	HIMS Hims & Hers Health	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$25.00 ➝ $26.00
8/11/2026	HIMS Hims & Hers Health	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$25.00 ➝ $30.00

(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GEHC GE HealthCare Technologies	$21.27B	1.54	$5.81 per share	12.48	$24.33 per share	2.98
HIMS Hims & Hers Health	$2.35B	3.14	$0.89 per share	35.64	$1.39 per share	22.75
LLY Eli Lilly and Company	$65.18B	16.97	$24.84 per share	47.31	$35.99 per share	32.65
NVO Novo Nordisk A/S	$46.80B	4.41	$4.59 per share	10.07	$6.58 per share	7.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GEHC GE HealthCare Technologies	$2.08B	$4.36	16.62	13.40	2.12	9.33%	20.12%	5.74%	11/4/2026 (Estimated)
HIMS Hims & Hers Health	$128.37M	-$0.63	N/A	63.26	N/A	-5.51%	-6.51%	-1.20%	11/9/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$29.80	39.43	25.62	1.40	33.53%	97.83%	23.23%	10/29/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.09	11.31	13.61	4.25	35.36%	61.20%	21.49%	11/4/2026 (Estimated)

Latest GEHC, LLY, NVO, and HIMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	HIMS Hims & Hers Health	-$0.0498	-$0.37	-$0.3202	-$0.37	$698.90 million	$753.21 million
8/5/2026	Q2 2026	LLY Eli Lilly and Company	$6.40	$8.38	+$1.98	$7.94	$20.82 billion	$22.97 billion
8/5/2026	Q2 2026	NVO Novo Nordisk A/S	$0.77	$0.96	+$0.19	$0.72	$10.89 billion	$11.98 billion
7/29/2026	Q2 2026	GEHC GE HealthCare Technologies	$1.04	$1.13	+$0.09	$1.24	$5.26 billion	$5.30 billion
6/30/2026	Q2 2026	NVO Novo Nordisk A/S	N/A	$0.9440	N/A	$0.72	N/A	$11.98 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GEHC GE HealthCare Technologies	$0.14	0.19%	N/A	3.21%	1 Years
HIMS Hims & Hers Health	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.92	0.59%	+15.18%	23.22%	11 Years
NVO Novo Nordisk A/S	$0.82	1.77%	+21.74%	20.05%	N/A

Latest GEHC, LLY, NVO, and HIMS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/22/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.59%	8/14/2026	8/14/2026	9/10/2026
8/5/2026	NVO Novo Nordisk A/S		$0.5786	2.58%	8/17/2026	8/17/2026	8/25/2026
6/30/2026	GEHC GE HealthCare Technologies	quarterly	$0.0350	0.23%	7/24/2026	7/24/2026	8/14/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GEHC GE HealthCare Technologies	0.92	1.26	0.97
HIMS Hims & Hers Health	4.21	0.93	0.87
LLY Eli Lilly and Company	1.41	1.35	1.00
NVO Novo Nordisk A/S	0.59	0.79	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GEHC GE HealthCare Technologies	82.06%
HIMS Hims & Hers Health	63.52%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%

Insider Ownership

Company	Insider Ownership
GEHC GE HealthCare Technologies	0.36%
HIMS Hims & Hers Health	11.76%
LLY Eli Lilly and Company	0.14%
NVO Novo Nordisk A/S	0.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GEHC GE HealthCare Technologies	54,000	451.69 million	450.06 million	Optionable
HIMS Hims & Hers Health	2,442	233.31 million	205.88 million	Optionable
LLY Eli Lilly and Company	50,000	941.36 million	940.04 million	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable

GEHC, LLY, NVO, and HIMS Headlines

Recent News About These Companies

Novo Nordisk files for oral weight loss pill approval in China

August 27 at 6:50 PM | qz.comQ

Novo Nordisk Could Be 54% Undervalued On Obesity Drug Setbacks

August 27 at 6:50 PM | finance.yahoo.com

Novo Nordisk stock falls as Deutsche Bank downgrades shares to sell

August 27 at 2:39 PM | invezz.comI

Deutsche Bank cuts Novo Nordisk to Sell after earnings, shares dip

August 27 at 1:50 PM | finance.yahoo.com

Novo Nordisk Stock Is Downgraded to Sell, and GLP-1s Aren’t the Reason

August 27 at 1:50 PM | finance.yahoo.com

Novo Nordisk Shares Drop as Bank Downgrade Reflects Growth Concerns

August 27 at 10:18 AM | wsj.com

GLP-1 maker hit with 'sell' rating as 2027 revenue cliff fears mount

August 27 at 8:58 AM | proactiveinvestors.co.uk

China's drug regulator accepts Novo Nordisk's application for oral Wegovy

August 27 at 8:49 AM | msn.com

Market Chatter: Novo Nordisk Reports China Regulators Accept Weight-Loss Drug Application

August 27 at 8:49 AM | finance.yahoo.com

Novo’s 2027 Growth Rebound Faces Fresh Doubts From Deutsche Bank – Even As China Wegovy Milestone Offers Retail Hope

August 27 at 8:49 AM | stocktwits.comS

GLP-1 maker hit with 'sell' rating as 2027 revenue cliff fears mount

August 27 at 8:49 AM | proactiveinvestors.com

Novo Nordisk A/S (NYSE:NVO) Stock Price Passes Above 200 Day Moving Average - What's Next?

August 27 at 1:43 AM | americanbankingnews.com

Novo Nordisk A/S (NYSE:NVO) Stock Passes Above Two Hundred Day Moving Average - Should You Sell?

August 27 at 1:40 AM | marketbeat.com

China drug regulator accepts Novo Nordisk's application for oral Wegovy

August 26 at 11:47 PM | reuters.com

Could Drug Dispute Shift Novo Nordisk (NYSE:NVO) Market Focus?

August 26 at 9:30 AM | kalkinemedia.comK

NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?

August 26 at 9:30 AM | finance.yahoo.com

NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?

August 26 at 9:21 AM | zacks.com

2 Stocks That Could Capitalize on the GLP-1 Boom

August 25 at 7:16 PM | fool.com

Eli Lilly vs Novo Nordisk: One Winner in The Weight-Loss Drug Gold Rush

August 25 at 10:30 AM | 247wallst.com

Novo Nordisk A/S - share repurchase programme

August 24, 2026 | finance.yahoo.com

Novo Nordisk (CPSE:NOVO B) Reaches LX9851 Obesity Drug Milestone

August 24, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GEHC, LLY, NVO, and HIMS Company Descriptions

GE HealthCare Technologies NASDAQ:GEHC

$72.48 -0.83 (-1.13%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$72.82 +0.34 (+0.47%)

As of 08/27/2026 07:55 PM Eastern

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Hims & Hers Health NYSE:HIMS

$31.63 +1.80 (+6.03%)

Closing price 08/27/2026 03:59 PM Eastern

Extended Trading

$31.38 -0.25 (-0.79%)

As of 08/27/2026 07:59 PM Eastern

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Eli Lilly and Company NYSE:LLY

$1,175.01 -14.40 (-1.21%)

Closing price 08/27/2026 03:59 PM Eastern

Extended Trading

$1,175.23 +0.22 (+0.02%)

As of 08/27/2026 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$46.27 -0.92 (-1.96%)

Closing price 08/27/2026 03:59 PM Eastern

Extended Trading

$46.39 +0.13 (+0.28%)

As of 08/27/2026 07:59 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GEHC, LLY, NVO, and HIMS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GEHC, LLY, NVO, and HIMS Earnings

Compare Dividends

Latest GEHC, LLY, NVO, and HIMS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GEHC, LLY, NVO, and HIMS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GEHC, LLY, NVO, and HIMS Company Descriptions

GE HealthCare Technologies NASDAQ:GEHC

Hims & Hers Health NYSE:HIMS

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools